AusperBio Secures $63 Million Series B2
Shanghai – September 21, 2025 – Cooley advised AusperBio, a privately held, clinical-stage biotechnology company dedicated to advancing targeted oligonucleotide therapies to achieve a functional cure for chronic hepatitis B (CHB), on its $63 million Series B2 financing. The round was co-led by Qiming Venture Partners and a globally renowned strategic investor, with additional participation from HanKang Capital, CDH Investments, YuanBio Venture Capital, Sherpa Capital and Genesis Capital.
Proceeds from the financing will be used to advance the clinical development of AHB-137, AusperBio’s lead product candidate, including the ongoing pivotal trial, multiple Phase II combination studies and expansion into global Phase II development. The funds will also support further advancement of the company’s proprietary Med-Oligo antisense oligonucleotide (ASO) platform, progression of its preclinical pipeline, scaling up of commercial manufacturing partnerships and long-term pipeline growth.
Lawyers Andrew Harline, Michael Shen and Lunga Su led the Cooley team advising AusperBio.
Cooley previously advised AusperBio on its $50 million Series B+ in May 2025, its $73 million Series B in December 2024 and its $37 million Series A in July 2024.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation.
Cooley has nearly 1,400 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of more than 3,000 people.
Related contacts
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.